1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Omeros Crashes To All-Time Low On IgAN Failure

 
• By Elizabeth Cairns

Development of narsoplimab in the kidney disease has been called off, making a forthcoming regulatory decision in a different use all the more important.      

Business man in suit looking at a red arrow pointing downwards, crashing through the ground in front of him
• Source: Shutterstock

October is not a lucky month for Omeros Corporation. Two years ago, narsoplimab was kicked back by the US Food and Drug Administration in its lead indication of stem cell transplant-associated thrombotic microangiopathy, knocking 26% off the company’s share price. Then yesterday, the company disclosed the failure of a Phase III trial in the drug’s next most advanced indication, immunoglobulin A nephropathy (IgAN).

Key Takeaways
  • Phase III ARTEMIS-IGAN trial has been toplined a failure

This time the loss of value was even worse. Omeros closed down 32%, taking the shares to an all-time low...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

More from R&D

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.